David C. Schwartz advises a broad range of clients in the life sciences, healthcare, and technology industries. David’s practice focuses on a variety of capital markets and corporate finance transactions, mergers and acquisitions, and securities law matters. He works with clients of all sizes, including startups and emerging businesses, publicly held middle-market companies, and venture capital firms and underwriters.
David regularly advises clients in connection with initial public offerings (IPOs), private investments in public equity (PIPEs), confidentially marketed public offerings, and direct follow-on offerings, in addition to venture capital, private equity, mergers and acquisitions, going-private, and other strategic transactions. He also acts as counsel for both public and private companies at various stages of development, providing general corporate representation and advice to boards of directors and management concerning corporate governance matters.
David is ranked in Chambers USA for his capital markets and M&A work, with one client noting that he “breaks things down in a simple way and takes time to explain things.” Another client highlighted that David is “not just an attorney but a real partner of ours.” A third client called David a "fantastic" lawyer who “always provides extremely helpful advice.”
David previously practiced as an associate at Morgan Lewis, and returned to the firm in 2019 after working as a partner at another global law firm and helping to establish its New Jersey office. There, he served as a member of its national leadership group of the US emerging growth and venture capital practice.
David is a frequent panelist on topics involving venture capital, public offerings, corporate governance, and corporate transactions. While attending law school, David worked in the Enforcement Division of the US Securities and Exchange Commission’s Philadelphia regional office.
Villanova University School of Law, 2001, J.D.
Lafayette College, 1998, B.A., with honors
Awards and Affiliations
Recommended, Industry focus: Healthcare: life sciences, The Legal 500 US (2020)
Recommended, M&A/corporate and commercial: M&A: large deals ($1bn+), The Legal 500 US (2020)